- Company
- Dong-A ST’s Nesp biosimilar export exceeds ₩10 bil.
- by An, Kyung-Jin May 3, 2021 05:53am
- The cumulative export sales of Dong-A ST’s biosimilar anemia treatment have exceeded 10 billion won. After entering the Japanese market through a partner company at the end of 2019, the sales of Dong-A ST's biosimilar have shown steady growth based on the increasing product recognition and favorable policies set on biosimilars by the Japa
- Company
- Yungjin won patent dispute on Abilify after 6 years
- by Kim, Jin-Gu May 3, 2021 05:53am
- Yungjin won the patent dispute between Otsuka and Yungjin over Abilify (Aripiprazole), a treatment for schizophrenia and bipolar disorder, in six years. This added Abilify's indication for bipolar disorder. Yungjin, which won the dispute, relieved the burden of compensation for damages caused by patent infringement. ◆Generic release
- Company
- SGLT-2 inhibitor combos drive sales in diabetes market
- by Kim, Jin-Gu Apr 30, 2021 06:10am
- The domestic sales of sodium-glucose transport protein-2 (SGLT-2) inhibitors in the diabetes treatment market have repeatedly marked rapid growth. The outpatient prescription sales of SGLT-2 inhibitors in Q1 this year increased by 14% from the previous year, continuing its double-digit growth. The growth is driven by combination thera
- Company
- Otsuka recently signed a co-promotion contract with Boryung
- by Apr 30, 2021 06:09am
- Otsuka will co-promote with Boryung to maintain IMD Mucosta SR in the Rebamipide market. The gastrointestinal drug Rebamipide market, worth &8361;100 billion, has recently been fiercely competitive. In December of last year, Yuhan (Recomid SR), GC Pharma (Mucotect SR), Daewoong Pharmaceutical (Mucotra SR), and Daewon Pharmaceutical (Bidre
- Company
- Will SK hand over Xarelto generic exclusivity rights to GC?
- by Kim, Jin-Gu Apr 29, 2021 06:09am
- SK Chemicals may decide to hand over the hard-won generic exclusivity for its generic version of ‘Xarelto (rivaroxaban) 2.5mg’ to GC Pharma. If GC Pharma takes over SK Chemicals’ generic exclusivity, the company will be able to enjoy market exclusivity for the low-dose Xarelto generic with Hanmi Pharmaceutical from this October to
- Company
- Epidiolex can be prescribed at general hospitals in Korea
- by Eo, Yun-Ho Apr 28, 2021 06:05am
- Epidiolex can be prescribed at general hospitals in Korea According to related industries, Epidiolex (Cannabidiol, CBD Oil), a hemp-based drug for the treatment of patients with rare and intractable diseases among children with epilepsy, has passed the drug commitee (DC) of Seoul National University Hospital. Epidiolex has been reimburs
- Company
- Viatris Korea-Jeil Pharm to co-promote Lipitor Plus from May
- by Eo, Yun-Ho Apr 28, 2021 06:05am
- On the 27th, Viatris Korea and Jeil Pharmaceutical announced that they will launch and co-promote the dyslipidemia treatment ‘Lipitor Plus (atorvastatin and ezetimibe)' from May 1st. Jeil Pharmaceutical had received approval for Lipitor Plus from the Ministry of Food and Safety on February 18th, in 3 dosages - 10/10mg, 10/20mg, 10/40mg
- Company
- Celltrion acquires Nesina and Actos from Takeda
- by Kim, Jin-Gu Apr 28, 2021 06:05am
- According to the pharmaceutical industry on the 26th, some of the 18 items that Celltrion acquired from Takeda last year are still being sold under the name of Takeda. This is because the license right in Korea has not yet been completely transferred to Celltrion. Celltrion acquired the rights of 18 items for chronic disease treatment a
- Company
- Generics for Eliquis have Rx amount of ₩12.7 billion
- by Kim, Jin-Gu Apr 28, 2021 06:05am
- It was found that Eliquis (Apixaban)'s cumulative prescription amount for generics, which faced a crisis of compensation for damages due to the Supreme Court decision made earlier this month, reached &8361;12.7 billion. With the sale of generics stopped at once after the Supreme Court ruling, generic companies have to pay a significant porti
- Company
- Roche Korea’s new NMOSD treatment Enspryng is approved
- by Eo, Yun-Ho Apr 27, 2021 06:05am
- Roche’s neuromyelitis optica spectrum disorder (NMOSD) treatment ‘Enspryng’ was approved in Korea. On the 25th, Roche Korea announced that the Ministry of Food and Drug Safety (MFDS) approved Enspryng (satralizumab) for the treatment of adults with aquaporin-4 antibody (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NM
